Trial Profile
A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Sponsors Bayer
- 26 Aug 2016 Status changed from active, no longer recruiting to completed.
- 25 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.
- 07 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.